CN101233135B - 用作非核苷反转录酶抑制剂治疗人免疫缺陷病毒的二芳基-嘌呤、二芳基-氮杂嘌呤和二芳基-脱氮嘌呤化合物 - Google Patents

用作非核苷反转录酶抑制剂治疗人免疫缺陷病毒的二芳基-嘌呤、二芳基-氮杂嘌呤和二芳基-脱氮嘌呤化合物 Download PDF

Info

Publication number
CN101233135B
CN101233135B CN2006800243079A CN200680024307A CN101233135B CN 101233135 B CN101233135 B CN 101233135B CN 2006800243079 A CN2006800243079 A CN 2006800243079A CN 200680024307 A CN200680024307 A CN 200680024307A CN 101233135 B CN101233135 B CN 101233135B
Authority
CN
China
Prior art keywords
phenyl
benzyl
chcn
cyano
dimethoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2006800243079A
Other languages
English (en)
Chinese (zh)
Other versions
CN101233135A (zh
Inventor
J·L·吉拉代
Y·科
S·肖
H·W·金
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ardea Biociences Inc
Original Assignee
Ardea Biociences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ardea Biociences Inc filed Critical Ardea Biociences Inc
Publication of CN101233135A publication Critical patent/CN101233135A/zh
Application granted granted Critical
Publication of CN101233135B publication Critical patent/CN101233135B/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/28—Oxygen atom
    • C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN2006800243079A 2005-05-05 2006-05-05 用作非核苷反转录酶抑制剂治疗人免疫缺陷病毒的二芳基-嘌呤、二芳基-氮杂嘌呤和二芳基-脱氮嘌呤化合物 Expired - Fee Related CN101233135B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US67866705P 2005-05-05 2005-05-05
US60/678,667 2005-05-05
PCT/US2006/017677 WO2006122003A2 (en) 2005-05-05 2006-05-05 Diaryl-purine, azapurines and -deazapurines as non-nucleoside reverse transcriptase inhibitors for treatment of hiv

Publications (2)

Publication Number Publication Date
CN101233135A CN101233135A (zh) 2008-07-30
CN101233135B true CN101233135B (zh) 2012-10-03

Family

ID=37397195

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2006800243079A Expired - Fee Related CN101233135B (zh) 2005-05-05 2006-05-05 用作非核苷反转录酶抑制剂治疗人免疫缺陷病毒的二芳基-嘌呤、二芳基-氮杂嘌呤和二芳基-脱氮嘌呤化合物

Country Status (12)

Country Link
US (2) US8227601B2 (https=)
EP (1) EP1877411B9 (https=)
JP (2) JP5138585B2 (https=)
CN (1) CN101233135B (https=)
AT (1) ATE541848T1 (https=)
AU (1) AU2006244195B2 (https=)
BR (1) BRPI0611455A2 (https=)
CA (1) CA2607021C (https=)
ES (1) ES2380951T3 (https=)
MX (1) MX2007013715A (https=)
WO (1) WO2006122003A2 (https=)
ZA (1) ZA200709481B (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602004031641D1 (de) * 2003-09-25 2011-04-14 Janssen Pharmaceutica Nv Die replikation von hiv hemmende purinderivate
WO2006122003A2 (en) 2005-05-05 2006-11-16 Ardea Biosciences, Inc. Diaryl-purine, azapurines and -deazapurines as non-nucleoside reverse transcriptase inhibitors for treatment of hiv
US20100298557A1 (en) * 2006-12-28 2010-11-25 Taisho Pharmaceutical Co., Ltd Pyrazolopyrimidine compound
ES2389752T3 (es) 2007-12-14 2012-10-31 Ardea Biosciences, Inc. Inhibidores de la transcriptasa inversa
UY31631A1 (es) 2008-02-06 2009-09-30 Nuevos derivados de 7-fenil-7h-pirrolo-[2,3d]-pirimidin-2-il-amino, sales de los mismos, procesos para su preparacion, composiciones farmacéuticas que los comprenden y aplicaciones
WO2010111406A2 (en) * 2009-03-24 2010-09-30 Myriad Pharmaceuticals, Inc. Compounds and therapeutic uses thereof
BR112015032546B1 (pt) * 2013-06-27 2022-05-17 Janssen Sciences Ireland Uc Derivados de pirrolo[3,2-d]pirimidina e composição farmacêutica que os compreende para o tratamento de infecções virais e outras doenças
EA201691831A1 (ru) 2014-04-25 2017-02-28 Пфайзер Инк. Гетероароматические соединения и их применение в качестве допаминовых d1 лигандов
AU2016219102B2 (en) 2015-02-13 2020-10-15 Dana-Farber Cancer Institute, Inc. LRRK2 inhibitors and methods of making and using the same
CN106188060A (zh) * 2015-04-29 2016-12-07 厦门大学 嘧啶并吡咯类化合物、其制备方法、药用组合物及其应用
KR102048719B1 (ko) * 2015-08-13 2019-11-26 베이징 한미 파마슈티컬 컴퍼니 리미티드 Irak4억제제 및 이의 용도
CN106117242B (zh) * 2016-06-27 2018-08-03 山东大学 四氢噻喃并嘧啶类衍生物及其制备方法与应用
CN107793417B (zh) * 2016-09-05 2020-06-09 复旦大学 吡咯并[2,3-d]嘧啶类化合物及其盐，及制备方法和药用用途
CN106749266B (zh) * 2016-11-14 2019-01-22 山东大学 吡咯并[2,3-d]嘧啶类化合物的高效制备方法
WO2022011171A1 (en) * 2020-07-08 2022-01-13 Klotho Therapeutics, Inc. Novel compounds and methods for increasing klotho gene expression
TW202415645A (zh) 2018-03-01 2024-04-16 愛爾蘭商健生科學愛爾蘭無限公司 ２，４－二胺基喹唑啉衍生物及其醫學用途
CN111499639B (zh) * 2019-01-31 2022-03-04 四川大学华西医院 嘧啶酮衍生物及其在制药中的应用
KR20230127228A (ko) * 2020-11-27 2023-08-31 올오리온 테라퓨틱스 인크. 아미노헤테로아릴 키나아제 억제제
AU2024266528A1 (en) * 2023-05-04 2025-10-16 Daewoong Pharmaceutical Co., Ltd. Novel heterocyclic amine derivatives and pharmaceutical composition comprising same
WO2025184609A1 (en) * 2024-03-01 2025-09-04 Gilead Sciences, Inc. Antiviral compounds

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005028479A2 (en) * 2003-09-25 2005-03-31 Janssen Pharmaceutica N.V. Hiv replication inhibiting purine derivatives

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ229453A (en) * 1988-06-10 1991-08-27 Univ Minnesota & Southern Rese A pharmaceutical composition containing purine derivatives with nucleosides such as azt, as antiviral agents
EP1129096B1 (en) 1998-11-12 2003-05-21 Neurocrine Biosciences, Inc. Crf receptor antagonists and methods relating thereto
WO2000037471A1 (en) * 1998-12-23 2000-06-29 Neurogen Corporation 2-amino-9-alkylpurines: gaba brain receptor ligands
CZ27399A3 (cs) 1999-01-26 2000-08-16 Ústav Experimentální Botaniky Av Čr Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
YU25500A (sh) * 1999-05-11 2003-08-29 Pfizer Products Inc. Postupak za sintezu analoga nukleozida
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
BRPI0407329A (pt) 2003-02-07 2006-01-10 Janssen Pharmaceutica Nv Derivados de pirimidina para a prevenção de infecção de hiv
AU2005298637B8 (en) 2004-10-29 2012-12-06 Janssen Sciences Ireland Uc HIV inhibiting bicyclic pyrimidine derivatives
WO2006122003A2 (en) * 2005-05-05 2006-11-16 Ardea Biosciences, Inc. Diaryl-purine, azapurines and -deazapurines as non-nucleoside reverse transcriptase inhibitors for treatment of hiv

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005028479A2 (en) * 2003-09-25 2005-03-31 Janssen Pharmaceutica N.V. Hiv replication inhibiting purine derivatives

Also Published As

Publication number Publication date
EP1877411B9 (en) 2012-08-29
JP2008540454A (ja) 2008-11-20
EP1877411A2 (en) 2008-01-16
CA2607021A1 (en) 2006-11-16
US8227601B2 (en) 2012-07-24
JP2012188454A (ja) 2012-10-04
WO2006122003A3 (en) 2007-01-04
AU2006244195A1 (en) 2006-11-16
US20120226037A1 (en) 2012-09-06
JP5138585B2 (ja) 2013-02-06
MX2007013715A (es) 2008-01-28
EP1877411A4 (en) 2008-10-22
CN101233135A (zh) 2008-07-30
ES2380951T3 (es) 2012-05-21
US20090124802A1 (en) 2009-05-14
ZA200709481B (en) 2008-11-26
ES2380951T9 (es) 2012-12-21
AU2006244195B2 (en) 2012-03-15
US8354532B2 (en) 2013-01-15
CA2607021C (en) 2013-10-29
WO2006122003A2 (en) 2006-11-16
BRPI0611455A2 (pt) 2010-09-08
ATE541848T1 (de) 2012-02-15
EP1877411B1 (en) 2012-01-18

Similar Documents

Publication Publication Date Title
CN101233135B (zh) 用作非核苷反转录酶抑制剂治疗人免疫缺陷病毒的二芳基-嘌呤、二芳基-氮杂嘌呤和二芳基-脱氮嘌呤化合物
TWI227235B (en) Bicyclic nitrogen heterocycles
JP2815617B2 (ja) 縮合ピリミジン誘導体およびその製造方法
JP5046942B2 (ja) Ｈｃｖ阻害性の二環式ピリミジン類
US7439240B2 (en) Purine-or pyrrolol[2,3-d]pyrimidine-2-carbonitiles for treating diseases associated with cysteine protease activity
TWI598343B (zh) 非核苷反轉錄酶抑制劑
KR100571339B1 (ko) 세포증식 억제제로서의 7-옥소 피리도피리미딘
AU2016370743B2 (en) Bipyrazolyl derivatives useful for the treatment of autoimmune diseases
AU2003267098A1 (en) Dihydroxypyridopyrazine-1,6-dione compounds useful as hiv integrase inhibitors
JP2006521398A (ja) ＴＧＦβの二−環式ピリミジン阻害剤
CN101443318A (zh) 作为激酶抑制剂的杂二环甲酰胺
EP1940846B9 (en) Pyrimidin-4-yl-3,4-dihydro-2h-pyrrolo[1,2a]pyrazin-1-one compounds
US6387912B1 (en) Utilization of pyrimidine derivatives for preventing and treating cerebral ischaemia
EP1636235A1 (en) Pyridinylpyrazolopyrimidinone derivatives as pde 7 inhibitors
Gatta et al. New [f]‐fused xanthines: Synthesis of 1, 3‐dipropyl‐1H, 3H‐pyrazino, pyrido, pyrimido and pyrrolo [2, 1‐f] purine‐2, 4‐diones
EP2905024A1 (en) Pyrido[2,3-d]pyrimidine-7(8H)-one derivatives for the treatment of infections caused by Flaviviridae
CN113150012B (zh) 吡唑并[1,5-a]吡嗪类衍生物及其制备方法和用途
TW202246261A (zh) 作為抗癌劑的化合物
AU2012203082A1 (en) Diaryl-purine, azapurines and -deazapurines as non-nucleoside reverse transcriptase inhibitors for treatment of HIV
CN120192323A (zh) 含有吡咯酮的化合物
HK1242310A1 (en) Purine derivatives for the treatment of viral infections
HK1197678A (en) Purine derivatives for the treatment of viral infections

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20121003

Termination date: 20210505

CF01 Termination of patent right due to non-payment of annual fee